Stock Events

Stock Events

Neuren Pharmaceuticals 

$12.17
48
+$0.00+0% Tuesday 15:32

Statistics

Day High
13.46
Day Low
12
52W High
14.8
52W Low
7.7
Volume
250
Avg. Volume
41
Mkt Cap
1.54B
P/E Ratio
84.13
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25AugExpected
Q3 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Next
0.01
0.35
0.69
1.03
Expected EPS
0.07363610414285716
Actual EPS
N/A

Financials

47.24%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
38.15MRevenue
18.02MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NURPF. It's not an investment recommendation.
NVIDIA
9
NVDA
Fortescue
9
FMG.AU
CSL
9
CSL.AU
Pro Medicus
7
PME.AU

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.49B
Acadia Pharmaceuticals targets central nervous system disorders, including rare diseases, similar to Neuren's therapeutic areas.
Biogen
BIIB
Mkt Cap29.4B
Biogen focuses on neurodegenerative diseases, multiple sclerosis, and spinal muscular atrophy, competing in the neurological space with Neuren.
PTC Therapeutics
PTCT
Mkt Cap7.04B
PTC Therapeutics works on rare disorders, including neurological diseases, making it a direct competitor to Neuren.
Ionis Pharmaceuticals
IONS
Mkt Cap9.63B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery for neurological diseases, competing with Neuren's focus.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.89B
Alnylam Pharmaceuticals develops RNAi therapeutics for neurological disorders, directly competing with Neuren's research focus.
Anavex Life Sciences
AVXL
Mkt Cap231.68M
Anavex Life Sciences focuses on neurodegenerative and neurological diseases, including Rett syndrome, a key area for Neuren.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is engaged in gene editing for various diseases, including potential treatments for neurological disorders, posing indirect competition to Neuren.

About

Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of treatments for neurological conditions. Their leading therapeutic compound, trofinetide, is currently undergoing pivotal (Phase III) clinical trials for Rett syndrome, and has also successfully completed Phase II trials targeting Fragile X syndrome. The company is also progressing NNZ-2591, which has finished its initial human trials (Phase I) for a spectrum of rare neurodevelopmental disorders, including Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Willi syndromes. In addition to its drug pipeline, Neuren provides development-related services and possesses investments in loan-backed shares. The firm was established in 2001 and operates from its base in Camberwell, Australia.
Show more...
CEO
Mr. Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), F.C.A.
Employees
8
Country
Other
ISIN
NZNEUE0001S8

Listings

STU
DE
NK9.STU
OTC Link
US
NURPF
AU
AU
NEU.AU
F
DE
NK9.F

0 Comments

Share your thoughts

FAQ

What is Neuren Pharmaceuticals stock price today?▼
The current price of NURPF is $12.17 USD — it has increased by +0% in the past 24 hours. Watch Neuren Pharmaceuticals stock price performance more closely on the chart.
What is Neuren Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Neuren Pharmaceuticals stocks are traded under the ticker NURPF.
What is Neuren Pharmaceuticals market cap?▼
Today Neuren Pharmaceuticals has the market capitalization of 1.54B
When is the next Neuren Pharmaceuticals earnings date?▼
Neuren Pharmaceuticals is going to release the next earnings report on August 25, 2026.
What were Neuren Pharmaceuticals earnings last quarter?▼
NURPF earnings for the last quarter are 0.08 USD per share, whereas the estimation was 0.01 USD resulting in a +777.04% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Neuren Pharmaceuticals revenue for the last year?▼
Neuren Pharmaceuticals revenue for the last year amounts to 38.15M USD.
What is Neuren Pharmaceuticals net income for the last year?▼
NURPF net income for the last year is 18.02M USD.
How many employees does Neuren Pharmaceuticals have?▼
As of July 22, 2026, the company has 8 employees.
In which sector is Neuren Pharmaceuticals located?▼
Neuren Pharmaceuticals operates in the Health & Wellness sector.
When did Neuren Pharmaceuticals complete a stock split?▼
The last stock split for Neuren Pharmaceuticals was on November 21, 2017 with a ratio of 1:20.
Where is Neuren Pharmaceuticals headquartered?▼
Neuren Pharmaceuticals is headquartered in Hawthorn East, Other.